Latest news with #Surgery
Yahoo
23-07-2025
- Business
- Yahoo
H1 25 Results: Increased Profitability Despite Subdued Revenues
Ad hoc announcement pursuant to Art. 53 LR MEDIA RELEASE Baar, Switzerland--(Newsfile Corp. - July 23, 2025) - Ad hoc announcement pursuant to Art. 53 LR Half-Year 2025 Results To view an enhanced version of this graphic, please visit: Increased profitability despite subdued revenues HALF-YEAR 2025 HIGHLIGHTS Revenue at CHF 225.4m, -6.5% (- 4.6% organic FX adj.). Healthcare segment grew 7.5% (organic FX adj.) driven by Dental and Surgery. Consumer & Industrial segment declined 10.9 % organic FX adj. on low commercial activity and project delays in Beauty Adj. EBITDA margin at 19.9%, +80 bps YoY on higher Dental volume and continued gross profit margin improvements in Industry Segment gross profit margin up 390 bps to 47.9%, positively impacting EBIT as a percentage of revenues (+170 bps) Free Cash Flow at CHF 11.4m (+50.9% yoy); Operating Net Cash Flow (ONCF) at CHF 15.3m (-24.1% yoy) reflecting inventory build-up mainly in Dental to mitigate potential tariff impact Well on track with Growth and Efficiency program: CHF 15m savings impact secured, CHF 8.5m realized in first half 2025 and 70 efficiency initiatives initiated Acceleration of cost out initiatives and CHF 3m additional actions identified, specifically targeted at Beauty business unit Strengthened leadership team: new CHRO, CTO and Business Unit Head Drug Delivery Revised 2025 revenue guidance: decline similar to that seen in H1 2025 (FX adj.) Confirmed 2025 profitability guidance: adjusted EBITDA margin 18% to 19% Confirmed mid-term guidance: CAGR in revenue of above 4%, adj. EBITDA margin of above 20% CEO René Willi said: 'We are on track with our strategy to pivot to high growth/high margin healthcare businesses. We have significantly improved profitability, which on the one hand is driven by strong growth in our most profitable Healthcare businesses Dental and Surgery, and on the other hand, by the impact of our Growth and Efficiency program. Our group revenues have been impacted by lower Beauty sales, which were the result of lower commercial activity, project delays and a high comparable in H1 2024. We have accelerated additional cost out measures of CHF 3m targeted at our Beauty business unit to maintain our high profitability levels.' Revenue key figures To view an enhanced version of this graphic, please visit: GROUP REVIEW In the first half of 2025, medmix generated revenue of CHF 225.4 million, 6.5% lower year-on-year. Foreign exchange rate effects of -2.0% negatively impacted underlying organic volume growth during the period which stood at -4.6%. Compared to the second half of 2024, however, Group revenues declined by -7.1% on a reported basis and by -5.1% organically. Healthcare segment revenue grew strongly in the first half of 2025, with two of the three Healthcare business units delivering robust year-on-year organic growth well above market rates, Surgery 26.1% and Dental 10.1%. Adverse impacts from Drug Delivery offset some of this growth. Healthcare segment revenues increased by 6.2% on a reported basis and 7.5% organically, with the difference of -1.3% entirely due to foreign exchange effects. Dental business unit organic revenue grew 10.1% year-on-year due to successful growth outside the historically strong impression material sector, resulting in above market growth additionally supported by stronger market conditions. Sequential organic revenues were down slightly 0.3%, partly due to uncertainty generated by US tariffs timing. Drug Delivery business unit revenue declined by 4.9% organically as H1 2024 included some non-repeat project milestones due to close out of a customer project. Surgery business unit revenue saw a 26.1% organic increase due to a lower base in H1 2024. Our customer base is growing as we move our commercial and manufacturing HQ to Atlanta. A continuation of the positive growth trajectory of the Dental and Surgery business units' revenue is expected in the second-half, at a more normalized level. The second source impact in the Drug Delivery business unit will again partly offset this growth. Consumer & Industrial segment organic revenue declined by 10.9%, driven by continued weakness in the Beauty markets and overall low consumer confidence. Industry business unit revenue reached CHF 63.5 million in the first half of 2025, organically 1.3% lower versus the first half of 2024. Sequentially, the Industry business unit delivered robust organic growth of 5.6% as we continue to deliver our full portfolio from our plant in Valencia and expand our greenLine offering. Management remains cautious of the global economic landscape and its impact on the Industry business unit. Beauty business unit organic revenue declined year-on-year by 17.7% to CHF 73.8 million, due to project delays and lower commercial activity in our business. In comparison, H1 2024 saw Beauty's highest half-year revenue in five years, where it benefited from a high level of launch activity after the lifting of covid restrictions. We expect this slower activity to continue in the second half. We have seen an increase in customer projects activity in Q2 2025, which will provide revenue growth momentum in 2026. Additionally, medmix has accelerated decisive cost-out measures to adapt the cost base to business volume and protect profitability. Gross profit margin, segment gross profit Segment gross profit, which does not include shared cost and cost absorption, grew by 1.6% to CHF107.9 million, despite a decline in Group revenues, delivering a strong margin of 47.9%. Healthcare segment gross profit increased by CHF 3.9 million, a growth of 7.5% year-on-year, in line with the revenue growth. Resulting segment gross profit margin was a strong 62.7%. Dental and Surgery segments margin growth was partly offset by the profit pressure from the Drug Delivery business unit as it remains in ramp-up mode, with more projects than commercial product sales. Consumer & Industrial first-half segment gross profit decreased by 4.0% year-on-year, due to the impact of decrease in Beauty volumes. Importantly, the segment delivered a robust gross profit margin of 38.3%, an increase of 370bps year-on-year, driven by operational efficiencies from our Growth and Efficiency program, driving margin expansion across both Industry and Beauty business units. Adjusted EBITDA Group Adjusted EBITDA was CHF 44.9 million, a decrease of 2.5% year-on-year, with our Growth and Efficiency program limiting the impact on profitability resulting from lower revenues. While there was a decline in the absolute Adjusted EBITDA, Adjusted EBITDA margin was 19.9%, having grown sequentially for two consecutive halves, compared to 19.1% in H1 2024 and 19.2% in H2 2024. The group delivered a robust profitability improvement of 80bps year-on-year, offsetting the impact of lower volumes and additional investments made in our Growth and Efficiency program. The year-on-year and sequential improvement is primarily driven by the continuation of strong Dental volumes and operational efficiencies in Consumer and Industrial segment. EBIT increased year-on-year from CHF 12.9 million to CHF 15.7 million, EBIT as a percentage of revenues increased 170bps to 7.0%. Net income Net income increased by CHF 1.4 million to CHF 6.9 million (thereof CHF 6.8 million attributable to shareholders of medmix AG) from CHF 5.6 million (thereof CHF 5.2 million attributable to shareholders of medmix AG) in the prior period. Operating Net Cash Flow (ONCF) Operating Net Cash Flow for H1 2025 decreased to CHF 15.3 million compared to the same period a year ago (CHF 20.1 million) mainly due to inventory build-up in the Dental business unit while Free Cash Flow increased from CHF 7.6 million in H1 2024 to CHF 11.4 million in the first half of 2025, mainly due to lower CAPEX, which may however increase in the second half. GROWTH & EFFICIENCY PROGRAM Our Growth and Efficiency program launched in 2024 aims at enhancing growth by re-allocating resources to our strategic priorities and improving our performance by strategically reducing costs. With CHF 15 million savings impact secured and CHF 8.5 million realized in the first half of 2025, we are on track with our goal for H1 2025. We have implemented 70 efficiency initiatives, such as reducing headquarters and support functions or automating productions processes in our factories. We will also continue to invest in our sales organization and in R&D, which will ensure we remain at the forefront of innovation in both our segments. This program will not impact our ability to maintain our innovation pace and quality standards and will ultimately lead to an increase in our service levels. STRENGTHENED LEADERSHIP TEAM In the past half year, we have significantly strengthened our management team with seasoned leaders. Jasper Den Ouden joined medmix as of March this year as Chief Human Resources and Sustainability Officer. Jasper brings extensive international HR leadership experience. He most recently served as Chief Human Resources Officer at SR Technics Group in Zurich where he led HR for 2,200 employees and drove key initiatives in digital transformation, talent development, ESG and organizational change. We are also very happy to welcome Francisco Faoro and Oliver Haferbeck to our Executive Leadership Team. Oliver was appointed as the new Head of Drug Delivery Business Unit in June. He brings a wealth of international leadership experience in the healthcare and medical technology sectors. Most recently, he served as Head of Gerresheimer Advanced Technology and CEO of Sensile Medical AG, where he led innovation in advanced drug delivery systems. His tenure at Gerresheimer was marked by a strong focus on strategic growth, technological advancement, and operational excellence. Francisco Faoro joined medmix as Chief Technology Officer in May. Francisco brings extensive international leadership experience in technology and innovation. He held multiple senior leadership roles at Straumann Group, successfully preparing multiple implant innovations creating significant growth momentum. Prior to his tenure in the dental field, Francisco had several managerial positions in brand management and product development within the orthopedic and polymer processing industries. OUTLOOK Based on H1 2025 actuals and our outlook for the full year, we now expect a full year revenue decline similar to that seen in H1 2025 on an FX adjusted basis. Our 2025 guidance for profitability with an adjusted EBITDA margin of 18-19% remains unchanged, as does our mid-term guidance –over a three-year period– with a compound annual growth rate in revenues of above 4% and an adj. EBITDA margin above 20%. Key figures To view an enhanced version of this graphic, please visit: The medmix half-year report is available to download here. Half-year 2025 results presentation Webcast participation medmix management will present the half-year results 2025 as a webcast on July 23, 2025, at 08:30 CET. A webcast invitation was sent to medmix news subscribers early July. If you have not received it and wish to participate, please click here to pre-register by 08:00 CET latest to receive the link to the webcast and dedicated dial-in details. Webcast playback The playback of the webcast will be available shortly after the event under the same link. Inquiries Investor Relations: investorrelations@ Media Relations: communications@ Key dates in 2025/2026 February 26, 2026 Full-year results 2025 About medmix medmix is a global leader in high-precision delivery devices. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2,700 employees provide our customers with uncompromising quality, proximity, and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). Disclaimer This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-07-2025
- Health
- Business Wire
Avvio Medical Announces New CPT Code for Its Breakthrough Kidney Stone Treatment Technology
SAN FRANCISCO--(BUSINESS WIRE)-- Avvio Medical, Inc., a company dedicated to revolutionizing the treatment of urinary stones, is excited to announce that the American Medical Association (AMA) has officially published the early release of a new Category III CPT code for Avvio's novel kidney stone treatment system. , CPT code 0991T will be used by healthcare providers and facilities nationwide to report procedures utilizing Avvio Medical's innovative technology. The new code, which reflects the final nomenclature approved by the AMA, marks a significant milestone in Avvio's journey to expand patient access, improve care, and streamline reimbursement for its groundbreaking approach. 'The introduction of a dedicated CPT code for our technology demonstrates the clinical importance of our ureteral stone solution,' said Paul Molloy, CEO, Avvio Medical. 'This achievement will help ensure that physicians and health systems can more easily offer our therapy to patients while benefiting from clear and accurate billing processes.' Avvio worked with expert reimbursement strategy consultants Jeffrey Dann, M.D., and PRIA Healthcare to support the code application process and overall market access planning. The announcement was made public as part of the AMA's official Category III CPT Code Early Release, available here. What This Means CPT 0991T will take effect January 1, 2026. The new code reflects important progress toward bringing Avvio's technology to patients and providers. This development highlights Avvio's commitment to advancing access and innovation in kidney stone care. About the Enhanced Lithotripsy System (ELS) The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers. About Avvio Medical Avvio Medical is a privately held company which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of urinary stones. The company's initial technology is designed to offer patients and healthcare professionals a fast, minimally invasive solution for treating urinary stone disease in various clinical or outpatient settings, eliminating the routine need for anesthesia or X-ray imaging. For more information, visit
NDTV
11-07-2025
- Entertainment
- NDTV
"Not Just For The Laughter But...":Gautam Adani On Why He Likes Munna Bhai Film
Rajkumar Hirani's Munna Bhai M.B.B.S served as a reminder that "true healing goes far beyond surgery", Adani Group Chairman Gautam Adani on Friday said, as he spoke about the movie that is one of his all-time favourites, "not just for the laughter, but for the message". Mr Adani was speaking at the 5th Annual Conference of the Society for Minimally Invasive Spine Surgery - Asia Pacific, when he shared an anecdote about his liking for the Sanjay Dutt-starrer movie. "Let me share something personal. One of my all-time favourite films is Munna Bhai MBBS. Not just for the laughter, but for the message. Munnabhai was not just healing people with medicine; he was healing them with humanity. It reminded us all that true healing goes far beyond surgery," he said. "One of my all-time favourite films is Munna Bhai MBBS. Not just for the laughter, but for the message. Munna Bhai was not just healing people with medicine; he was healing them with humanity. It reminded us all that true healing goes far beyond surgery. Healing is hope. Healing is humanity," he added. Healing is hope and healing is humanity, the industrialist said. "As Munna Bhai said - be it a magic trick or a surgery - there is only one thing common in both, and that is, humanity," he said. Mr Adani recalled the time when he made the bold decision of leaving for Mumbai at the age of 16. "I bought a second-class train ticket and left for Mumbai with no degree, no job, and no backup except a burning desire to define my own path. If you want something from your heart, then the whole universe becomes interested in introducing him to you," he said. In Mumbai, he said, he began learning to "sort and polish diamonds". "Each stone I polished taught me patience, precision, and perseverance. My first deal with a Japanese buyer earned me Rs 10,000 in commission. The money never mattered. The moment did - because that was the moment when I realized that my beliefs would have to always outpace my doubts," he said. "And that is the truth about entrepreneurship. It never begins with a grand vision. It begins with a spark of conviction," he added. It begins with the courage to act, even when the future is uncertain, Mr Adani said. "And it begins with the willingness to dream alone and then walk alone, before others join the path," he added.
Indian Express
02-07-2025
- Health
- Indian Express
Podcaster claims the Hemoglobin A1C test to measure blood sugar levels can help detect cancer risk: ‘It's one of the most important…'; experts react
Is there a link between the Hemoglobin A1C blood test, which measures blood sugar levels, and the identification of cancer risk? Podcaster Bisma Lalji, who is battling stage 4 breast cancer, recently claimed that high blood sugar doesn't just impact diabetes risk, 'It also fuels inflammation, disrupts hormone balance, and creates an internal environment where cancer can grow and thrive.' In an Instagram post, she added that the A1C test, which measures your average blood sugar levels over the past ~3 months, is 'one of the most important, especially when it comes to cancer.' 'Cancer cells literally feed off glucose,' Lalji, who hosts The Other C Word podcast, continued. Sharing that glucose management is now a core part of her healing plan, she wrote: 'I was diagnosed with stage 4 breast cancer at 35, and since then, I've adopted the metabolic approach to cancer-focused on stabilising blood sugar, reducing insulin spikes, and supporting my mitochondria'. She also mentioned that she follows a Ketogenic diet, practices intermittent fasting, and regularly tracks her glucose, 'Not for weight loss—but to starve cancer, reduce inflammation, and protect my body. Whether you have cancer or not, your A1C matters. You should be getting it checked at least every 3 months if you're working on improving your metabolic health—or, at minimum, once a year as part of your annual labs. Don't assume your doctor is already checking it. You have to ask,' stressed Lalji. Before answering the question, let's understand the tests generally carried out to gauge cancer risk. Dr Neeraj Goel, director, oncology services, GI Oncology, GI & HPB Surgery at the CK Birla Hospital®, Delhi, said that it's essential to consider a combination of factors rather than relying on a single test. 'Cancer risk is influenced by personal medical history, such as previous cancer diagnoses or pre-existing conditions like ulcerative colitis, which may elevate the likelihood of certain cancers. Family medical history also plays a significant role—having a close relative with cancer can increase your risk, especially if inherited genetic mutations like BRCA1 or BRCA2 are involved, which are known to significantly raise the chances of breast, ovarian, and some other cancers,' said Dr Goel. Lifestyle factors such as smoking, poor diet (particularly one high in processed meats and saturated fats and low in fruits and vegetables), physical inactivity, and obesity are well-established contributors to increased cancer risk. 'In addition, environmental exposures—including ultraviolet (UV) radiation, ionising radiation, and certain chemical exposures—can also elevate the risk,' said Dr Goel. Dr Jyoti Anand, senior consultant in medical oncology at Fortis Hospital, Noida, added that several types of tests can help gauge an individual's risk of developing cancer. These include genetic tests, blood tests, and imaging scans. Genetic testing is a valuable tool for individuals with a strong family history of cancer. According to Dr Goel, it can identify inherited mutations that may predispose someone to specific types of cancer. 'Alongside this, genetic counselling is important to help individuals understand their results and make informed decisions about preventive measures,' said Dr Goel. Risk assessment tools exist, such as the Gail model for estimating breast cancer risk and other models that consider age, family history, and personal health factors to estimate the likelihood of developing different cancers. Regular screening and early detection are among the most effective approaches to managing cancer risk. 'Screening tests such as mammograms, colonoscopies, Pap smears, and low-dose CT scans for high-risk individuals can help detect cancer at an early, more treatable stage, significantly improving outcomes and survival rates,' said Dr Goel. Dr Jyoti said the type of test recommended depends on an individual's personal risk factors, family medical history, and the presence of any symptoms or clinical findings. 'A doctor will guide you on the appropriate tests based on a comprehensive risk assessment. ' So, is HbA1c a reliable test? Dr Goel clarified that HbA1c, a blood test commonly used to assess long-term blood sugar control in individuals with diabetes, is not a test to detect or indicate cancer. 'While some studies have suggested a potential link between high HbA1c levels and increased cancer risk, no direct or definitive association has been established. Therefore, it should not be used as a cancer risk assessment tool. More research is needed in this area to draw firm conclusions,' said Dr Goel. However, if there are warning signs, consulting doctors may order blood tests like tumor markers or a Complete Blood Count (CBC). Dr Prashant Chandra, oncosurgeon, TGH Oncolife Cancer Centre, Pune, said that these tests need to be interpreted by an expert oncologist as tumour markers may remain normal in cancer patients and may be elevated in normal individuals. A post shared by Bisma Lalji | The Other C Word Podcast (@bismalalji) 'So don't panic with any reports, stay vigilant regarding your health, and know your personal and family history. Doing so can guide you on which tests are right for you. Remember to take any test advised by the doctor without any delay. Stick to the guidelines given by the doctor when it comes to treatment,' said Dr Chandra. DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
Fox News
28-06-2025
- Entertainment
- Fox News
David Beckham hospitalized for surgery related to soccer injury
Victoria Beckham shared a photo on social media Friday of husband David Beckham recovering in a hospital bed. "Get well soon daddy," she captioned the post on her Instagram Story. David went to the hospital for surgery to repair issues relating to a playing injury from his England career, Fox News Digital has learned. He broke his wrist in May 2003 in a match between England and South Africa in Durban, South Africa. In the photo, David smiled for the camera while lying on a hospital bed in a gown with a blue arm sling around his neck. Victoria shared a second photo that showed the former soccer player wearing a bracelet with beads that spelled out "Get well soon." David began playing soccer professionally with Manchester United in 1992. He finally retired in 2013 after playing for the LA Galaxy for five years. David was knighted by King Charles III earlier this month for his services to sports and charity, meaning he is now known as Sir David Beckham, and Victoria is Lady Beckham. "Growing up in east London with parents and grandparents who were so patriotic and proud to be British, I never could have imagined I would receive such a truly humbling honour," he shared in a statement at the time. "You've always been my knight in shining armour, but now it's official. Sir @davidbeckham!!! What an honour, I couldn't be prouder of you," Victoria wrote on Instagram after the announcement. The fashion designer also gushed over her husband on Father's Day, writing on Instagram, "Happy Father's Day to the best daddy there is! You always lead with love and our four beautiful children are a reflection of that. We all love you so so much!!" The couple share four children: Brooklyn, 26, Romeo, 22, Cruz, 20, and Harper, 13.
